Invention Grant
- Patent Title: Rspondins as modulators of angiogenesis and vasculogenesis
-
Application No.: US16357765Application Date: 2019-03-19
-
Publication No.: US10538563B2Publication Date: 2020-01-21
- Inventor: Christof Niehrs , Olga Kazanskaya , Bisei Okawara
- Applicant: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS
- Applicant Address: DE Heidelberg
- Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS
- Current Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS
- Current Assignee Address: DE Heidelberg
- Agency: Hoffmann & Baron, LLP
- Priority: EP06022070 20061020
- Main IPC: A61K48/00
- IPC: A61K48/00 ; C07H21/02 ; C07H21/04 ; C07K14/475 ; C12Q1/6883 ; C07K16/18 ; A61K38/17 ; C12N15/113 ; G01N33/74 ; C07K14/515 ; A61K39/395

Abstract:
The present invention relates to the use of Rspondins, particularly Rspondin2 (Rspo2) or Rspondin3 (Rspo3) or Rspondin nucleic acids, or regulators or effectors or modulators of Rspondin, e.g. Rspo2 and/or Rspo3 to promote or inhibit angiogenesis and/or vasculogenesis, respectively. The invention is based on the demonstration that Rspo3 and Rspo2 arc angiogenesis promoters, and the identification of Rspo2 and 3 as positive regulators of vascular endothelial growth factor (VEGF). These results indicate a major role for Rspondins, particularly Rspo3 and/or Rspo2 in the signaling system during angiogenesis. The invention also relates to the use of regulators or effectors or modulators of Rspondin3, including agonists and antagonists, in the treatment of conditions where treatment involves inhibiting or promoting angiogenesis and/or vasculogenesis.
Public/Granted literature
- US20190359664A1 RSPONDINS AS MODULATORS OF ANGIOGENESIS AND VASCULOGENESIS Public/Granted day:2019-11-28
Information query